This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
For example, a reactivity ratio that is less than one for component 1 indicates that this component reacts with the other type of monomer more readily. Given this information, which is available for a multitude of monomer combinations in the "Wiley Database of Polymer Properties", the Mayo-Lewis equation can be used to predict the composition of the polymer product for all initial mole fractions of monomer. This equation is derived using the Markov model, which only considers the last segment added as affecting the kinetics of the next addition; the Penultimate Model considers the second-to-last segment as well, but is more complicated than is required for most systems. When both reactivity ratios are less than one, there is an azeotropic point in the Mayo-Lewis plot. At this point, the mole fraction of monomer equals the composition of the component in the polymer. There are several ways to synthesize random copolymers. The most common synthesis method is free radical polymerization; this is especially useful when the desired properties rely on the composition of the copolymer rather than the molecular weight, since free radical polymerization produces relatively disperse polymer chains. Free radical polymerization is less expensive than other methods, and produces high-molecular weight polymer quickly. Several methods offer better control over dispersity. Anionic polymerization can be used to create random copolymers, but with several caveats: if carbanions of the two components do not have the same stability, only one of the species will add to the other.
== History == In the 1960s, the adamantane derivative amantadine (1-aminoadamantane) was developed as an antiviral drug for the treatment of influenza. Other adamantane antivirals subsequently followed, such as rimantadine (1-(1-aminoethyl)adamantane) and adapromine (1-(1-aminopropyl)adamantane). It was serendipitously discovered in 1969 that amantadine possesses central dopaminergic stimulant-like properties, and subsequent investigation revealed that rimantadine and adapromine also possess such properties. Amantadine was then developed and introduced for the treatment of Parkinson's disease due to its ability to increase dopamine levels in the brain. It has also notably since been used to help alleviate fatigue in multiple sclerosis. With the knowledge of the dopaminergic stimulant effects of the adamantane derivatives, bromantane, which is 2-(4-bromophenylamino) adamantane, was developed in the 1980s at the Zakusov State Institute of Pharmacology, USSR Academy of Medical Sciences (now the Russian Academy of Medical Sciences) in Moscow as "a drug having psychoactivating and adaptogen properties under complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.)". It was found to produce more marked and prolonged stimulant effects than the other adamantanes, and eventually entered use. The drug was notably given to soldiers in the Soviet and Russian militaries to "shorten recovery times after strong physical exertion".
=== The Black Box === Valve planned on releasing an additional compilation for Windows entitled The Black Box, which would have contained only the three new games released as a part of the Orange Box—Half-Life 2: Episode Two, Portal, and Team Fortress 2. The Black Box was later cancelled for retail and only made available through Steam exclusively to owners of certain ATI graphics cards, who received a voucher for a free copy of The Black Box. During development, the simultaneous release of two game compilation packages with different content combinations was touted by Valve as a new direction for the game industry. Gabe Newell, co-founder of Valve, said, "The Black Box and The Orange Box represent a new approach to publishing multiple products on multiple platforms." After first discontinuing The Black Box, however, Valve released all the new material for individual download via Steam. The Black Box was to be priced US$10 lower than The Orange Box which would have made it $39.95 on PC and $49.95 on console in the U.S. if it used The Orange Box launch price as a baseline. To compensate for the cancellation of The Black Box, Valve offered gift subscriptions to Steam users who had previously purchased Half-Life 2 or Half-Life 2: Episode One and then purchased The Orange Box so that they could give their second copies of those two games as gifts to people added to their Steam Friends list. Still, the cancellation of The Black Box sparked complaints from game critics and consumers alike, unhappy that they were obliged to pay for games that they already owned.
Sources: en.wikipedia.org
=== Cape Colony === In parts of Cape Colony, particularly the Cape Midlands District where Boers formed a majority of the white inhabitants, the British had always feared a general uprising against them. In fact, no such uprising took place, even in the early days of the war when Boer armies had advanced across the Orange. The cautious conduct of some elderly Orange Free State generals had been one factor that discouraged the Cape Boers from siding with the Boer republics. Nevertheless, there was widespread pro-Boer sympathy. Some Cape Dutch volunteered to help the British, but a larger number volunteered to help the other side. Politics was more important than the military factor: the Cape Dutch, according to Milner 90 percent of whom favoured the rebels, controlled the provincial legislature, and its authorities forbade the British Army to burn farms or to force Boer civilians into concentration camps. The British had more limited options to suppress the insurgency in the Cape Colony as result. After he escaped across the Orange in March 1901, de Wet had left forces under Cape rebels Kritzinger and Gideon Scheepers to maintain a guerrilla campaign in the Cape Midlands. The campaign here was one of the least chivalrous of the war, with intimidation by both sides of each other's civilian sympathisers. In one of many skirmishes, Commandant Johannes Lötter's small commando was tracked down by a much-superior British column and wiped out at Groenkloof.
The disorder prediction category is a part of biannual CASP experiment that is designed to test methods according accuracy in finding regions with missing 3D structure (marked in PDB files as REMARK465, missing electron densities in X-ray structures). Disorder prediction can be more complicated for de novo-emerged and orphan proteins, which often lack detectable homologs and are generally shorter than "classical" proteins, reducing the reliability of predictors trained largely on conserved, globular proteins. Comparative benchmarks further show that structure/disorder predictors behave differently on de novo and random proteins than on conserved proteins, including different relationships between predicted disorder and confidence scores of 3D structure predictors, such as AlphaFold and ESMfold.
Having considered the data provided, and other relevant information available in scientific literature, the SCCS cannot conclude on the safety of the hydroxyapatite composed of rod–shaped nanoparticles for use in oral-care cosmetic products at the maximum concentrations and specifications given in this Opinion. This is because the available data/information is not sufficient to exclude concerns over the genotoxic potential of HAP-nano. The European Commission's Scientific Committee on Consumer Safety (SCCS) reissued an updated opinion in 2023, where it cleared rod-shaped nano hydroxyapatite of concerns regarding genotoxicity, allowing consumer products to contain concentrations of nano hydroxyapatite as high as 10% for toothpastes and 0.465% for mouthwashes. However, it warns of needle-shaped nano hydroxyapatite and of inhalation in spray products. It stated:
On October 30, 2023, President Biden released Executive Order 14110 on Safe, Secure, and Trustworthy Artificial Intelligence. The Executive Order includes directives on standards for critical infrastructure, AI-enhanced cybersecurity, and federally funded biological synthesis projects. The Executive Order provides the authority to various agencies and departments of the US government, including the Energy and Defense departments, to apply existing consumer protection laws to AI development. The Executive Order builds on the Administration's earlier agreements with AI companies to instate new initiatives to "red-team" or stress-test AI dual-use foundation models, especially those that have the potential to pose security risks, with data and results shared with the federal government. The Executive Order also recognizes AI's social challenges, and calls for companies building AI dual-use foundation models to be wary of these societal problems. For example, the Executive Order states that AI should not "worsen job quality", and should not "cause labor-force disruptions". Additionally, Biden's Executive Order mandates that AI must "advance equity and civil rights", and cannot disadvantage marginalized groups. It also called for foundation models to include "watermarks" to help the public discern between human and AI-generated content, which has raised controversy and criticism from deepfake detection researchers. Biden also issued a National Security Memorandum on Artificial Intelligence in October 2024. Federal grantmaking emerged as a mechanism of AI governance.
Sources: en.wikipedia.org
=== Occlusion and hydration === Silicone gel sheets occlude and hydrate the stratum corneum of the treated skin area. The stratum corneum normally conserves water and acts as a barrier to microbial infection. Its function can be disrupted by wound formation. The stratum corneum of hypertrophic scars and keloids absorbs more water than normal skin, depleting the water supply from the stratum corneum. Excessive dehydration of keratinocytes stimulates cytokine production, leading to increased collagen production. After applying the sheet, the rate of water loss via evaporation of the treated skin area is half of the untreated area. Therefore, the sheet prevents the drying up of stratum corneum, and thus further collagen production. Collagen production exacerbates the growth of hypertrophic scars and keloids and thus should be avoided. Hydrating a scar over a prolonged period can also relieve symptoms such as itching and pain. Such an effect is likely due to decreased capillary activity and thus local collagen deposition.
Tyrannosaurus () is a genus of large theropod dinosaur. The type species Tyrannosaurus rex (rex meaning 'king' in Latin), often shortened to T. rex or colloquially T-Rex, is one of the best represented theropods. It lived throughout what is now western North America, on what was then an island continent known as Laramidia. Tyrannosaurus had a much wider range than other tyrannosaurids. Fossils are found in a variety of geological formations which have been dated to the late Maastrichtian age of the late Cretaceous period, 69 to 66 million years ago, with isolated specimens possibly indicating an earlier origin in the middle Campanian age. It was one of the last known members of the tyrannosaurids and among the last non-avian dinosaurs to exist before the Cretaceous–Paleogene extinction event. Like other tyrannosaurids, Tyrannosaurus was a bipedal carnivore with a massive skull balanced by a long, heavy tail. Relative to its large and powerful hind limbs, the forelimbs of Tyrannosaurus were short but unusually powerful for their size, and they had two clawed digits. The most complete specimen measures 12.3–12.4 m (40–41 ft) in length, but according to most modern estimates, Tyrannosaurus could have exceeded sizes of 13 m (43 ft) in length, 3.7–4 m (12–13 ft) in hip height, and 8.8 t (8.7 long tons; 9.7 short tons) in mass. Although some other theropods might have rivaled or exceeded Tyrannosaurus in size, it is still among the largest known land predators, with its estimated bite force being the largest among all terrestrial animals.
== History == The first reported chemical synthesis of HMB was published in 1877 by the Russian chemists Michael and Alexander Zaytsev. HMB was isolated from the bark of Erythrophleum couminga (a Madagascan tree) in 1941 by Leopold Ružička. The earliest reported isolation of HMB as a human metabolite was by Tanaka and coworkers in 1968 from a patient with isovaleric acidemia. The effects of HMB on human skeletal muscle were first discovered by Steven L. Nissen at Iowa State University in the mid-1990s. Nissen founded a company called Metabolic Technologies, Inc. (MTI) around the time of his discovery, which later acquired six HMB-related patents that the company has used to license the right to manufacture and incorporate HMB into dietary supplements. When it first became available commercially in the late 1990s, HMB was marketed solely as an exercise supplement to help athletes and bodybuilders build muscle. MTI subsequently developed two HMB-containing products, Juven and Revigor, to which Abbott Nutrition obtained the market rights in 2003 and 2008 respectively. Since then, Abbott has marketed Juven as a medical food and the Revigor brand of HMB as an active ingredient in food products (e.g., certain formulations of Ensure) and other medical foods (e.g., certain formulations of Juven).
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.